Regulating gabapentin as a drug of abuse: A survey study of Kentucky community pharmacists.
Attitude of Health Personnel
Community Pharmacy Services
Controlled Substances
/ classification
Drug and Narcotic Control
/ legislation & jurisprudence
Gabapentin
/ therapeutic use
Humans
Kentucky
Pharmacists
Prescription Drug Misuse
/ legislation & jurisprudence
Prescription Drug Monitoring Programs
/ legislation & jurisprudence
Prescription Drugs
Surveys and Questionnaires
/ statistics & numerical data
Journal
Journal of the American Pharmacists Association : JAPhA
ISSN: 1544-3450
Titre abrégé: J Am Pharm Assoc (2003)
Pays: United States
ID NLM: 101176252
Informations de publication
Date de publication:
Historique:
received:
24
07
2018
revised:
07
12
2018
accepted:
20
12
2018
pubmed:
23
2
2019
medline:
22
7
2020
entrez:
22
2
2019
Statut:
ppublish
Résumé
As the number of gabapentin prescriptions has increased, so have reports of its misuse and diversion. This trend has led some states to closer monitoring of gabapentin dispensing through prescription drug monitoring programs (PDMPs). The objective of this study was to collect and analyze Kentucky community pharmacists' perceptions of gabapentin misuse and diversion, and their support or opposition to regulatory efforts to reclassify the drug as a controlled substance (CS). Responses were collected using an online survey sent by e-mail to all pharmacists practicing in Kentucky in August 2016. The survey collected basic demographic characteristics and pharmacists' experience with gabapentin dispensing. Descriptive statistics were calculated using question response frequencies. Pearson's chi-squared statistics were calculated to examine the distribution of support for gabapentin as a CS in Kentucky across each of the categories of the individual variables. Logistic regression was used to estimate the effects of pharmacist demographic characteristics and experiences with gabapentin on their support of gabapentin reclassification as a CS. One thousand seven hundred sixty-nine surveys were collected (response rate = 34.2%). Responding community pharmacists (n = 1084) believe that the abuse and diversion of gabapentin are a problem in their communities, with 9 in 10 (89.6%) indicating that they agree or strongly agree. More than three-fourths (87.5%) indicated support for reclassifying gabapentin as a CS. Common reasons for opposition to gabapentin regulatory changes were that they would not reduce or eliminate abuse (45.8%) and that they would be an inconvenience to patients (17.0%). Pharmacists practicing in independent pharmacies and pharmacists in practice greater than 20 years were less likely to indicate support for gabapentin reclassification. Kentucky community pharmacists express considerable concern over the possible misuse and diversion of gabapentin and widely support regulatory changes reclassifying gabapentin as a CS.
Identifiants
pubmed: 30786971
pii: S1544-3191(18)30585-5
doi: 10.1016/j.japh.2018.12.018
pmc: PMC9251728
mid: NIHMS1817535
pii:
doi:
Substances chimiques
Controlled Substances
0
Prescription Drugs
0
Gabapentin
6CW7F3G59X
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
379-382Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001998
Pays : United States
Informations de copyright
Copyright © 2019 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.
Références
Drug Alcohol Depend. 2018 May 1;186:80-85
pubmed: 29554591
Pharmacopsychiatry. 1999 May;32(3):107-9
pubmed: 10463378
JAMA Intern Med. 2014 Jan;174(1):70-7
pubmed: 24190578
Exp Brain Res. 2014 Aug;232(8):2535-9
pubmed: 24668130
Pain Res Manag. 2007 Summer;12(2):85-92
pubmed: 17505569
Pain. 2002 Oct;99(3):557-566
pubmed: 12406532
Ann Pharmacother. 1994 Oct;28(10):1188-96
pubmed: 7841578
Alcohol Clin Exp Res. 2009 Sep;33(9):1582-8
pubmed: 19485969
Anaesthesia. 2015 Oct;70(10):1186-204
pubmed: 26300519
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Drugs. 2017 Mar;77(4):403-426
pubmed: 28144823
JAMA. 2018 Feb 27;319(8):818-819
pubmed: 29486015
Anesth Analg. 2016 Apr;122(4):976-85
pubmed: 26991615
BMC Med Res Methodol. 2015 Apr 09;15:32
pubmed: 25888346
J Clin Psychopharmacol. 1997 Oct;17(5):423-4
pubmed: 9315994
Addiction. 2016 Jul;111(7):1160-74
pubmed: 27265421
Arch Intern Med. 2006 May 8;166(9):1021-6
pubmed: 16682577
Subst Abuse. 2018 Sep 23;12:1178221818801311
pubmed: 30262984
J Eval Clin Pract. 2015 Aug;21(4):688-93
pubmed: 25929295